The expected services are divided into two lots (each lot giving rise to the award of a separate contract):

- Lot n°1 - Efficacy benefits of RCT001 in PDX models of uveal melanoma in mice;

- Lot n°2 - Bioavailability services.

Lot n°1 - Efficacy benefits of RCT001 in PDX models of uveal melanoma in mice. For this batch n°1, the expected benefits are divided into 2 phases: - Phase 1: Efficacy of RCT001 on 12 different Uveal Melanoma PDX; - Phase 2: Characterization of the effect of RCT001 on invasion and polarization of macrophages within by 2 PDX different.

Lot n°2 - Bioavailability benefits.For this batch n°2, the expected benefits are divided into 2 phases: - Phase 1: Bioavailability study in Rats; - Phase 2: Bioavailability study in Dogs.